ClinicalTrials.gg
Not yet recruitingNCT07635914Updated Jun 9, 2026

A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension

A Phase 3 interventional study of Aprocitentan tablets(SYH9108) and Placebo in Resistant Hypertension, sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
382
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Aprocitentan tablets are currently the only endothelin dual receptor antagonist approved internationally for the treatment of resistant hypertension.This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of aprocitentan tablets(SYH9108) in patients with treatment-resistant hypertension (rHTN)

Read the detailed description

The study consists of a screening period (up to 2 weeks), a run-in period (4 weeks), a treatment period (8 weeks), and a follow-up period. During the study, all participants should continue their background antihypertensive medications (at the same agents and dosages as used within 4 weeks prior to screening) and maintain lifestyle interventions such as a low-salt diet.

02

Conditions studied

  • Resistant Hypertension

Browse trials for

Keywords

  • Resistant hypertension
  • rHTN
  • Aprocitentan
  • SYH9108
03

In context

Hypertension

6,125 studies on the registry are indexed under Hypertension; 909 are open to participants now.

This study's planned enrollment of 382 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. is the lead sponsor of 30 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants must be ≥18 years of age.
  2. Participants must have received stable doses of ≥3 antihypertensive agents from distinct pharmacological classes for at least 4 weeks prior to signing the ICF, with such therapy maintained until randomization.
  3. During the screening period and prior to randomization, SiSBP ≥140 mmHg with or without SiDBP ≥90 mmHg, and SiSBP \<180 mmHg and SiDBP \<110 mmHg.
  4. Participants are able to understand and cooperate in completing this trial, voluntarily participate in the trial, and sign the Form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. Presence of secondary hypertension.
  2. Have had , stroke, unstable angina pectoris, or acute myocardial infarction occurring within the period from 12 months prior to signing the ICF up to randomization.
  3. From screening to prior to randomization, have presence of uncontrolled severe disease or life-threatening disease, or failure to recover from major surgery, or prior thyroid surgery, or presence of malignant tumor, or meeting the criteria for severe hepatic insufficiency at screening.
  4. Have had unstable cardiac disease occurring within the period from 6 months prior to signing the ICF up to randomization.
  5. Have received dialysis at any time prior to signing the ICF or prior to randomization.
  6. Type 1 diabetes.
  7. Compliance with any background antihypertensive drug or placebo is \<80% or >120% during the run-in period.
  8. Use of endothelin receptor antagonists, antihypertensive drugs other than background medications, or other blood pressure-affecting drugs, or high-dose loop diuretics from 4 weeks prior to signing the ICF until randomization; or use of oligonucleotide antihypertensive agents within 1 year prior to signing the ICF.
  9. or suspected hypersensitivity to the of the product, endothelin receptor antagonists, or background antihypertensive drugs, or potential hypersensitivity to the investigational product.
  10. Participated in other clinical trials and received at least one dose of study treatment within 12 weeks prior to signing the ICF.
  11. Average night shifts are ≥ 2 times per week during the 4 weeks prior to signing the ICF, the screening period, the run-in period, or the anticipated study period.
  12. History of drug abuse or alcohol abuse within 5 years prior to signing the ICF.
  13. Any of the following test results during the screening period or prior to randomization:

1) ≥37.5 kg/m2. 2) \< 100 g/L; 3) NT-proBNP ≥ 500 pg/mL; 4) : > 450 ms in males, > 470 ms in females; 5) \< 15 mL/min/1.73 m²; 6) or AST > 3 × , or total > 1.5 × ULN; 7) > 8.0%; 8) TSH outside the normal range and FT3 and/or FT4 outside the normal range; 9) Positive and positive HBV-DNA, or positive for any of anti- antibody, anti- antibody, anti-Treponema pallidum antibody.

14. Female participants of who are pregnant, breastfeeding, or have a positive pregnancy test from signing the ICF until randomization; or female participants of childbearing potential and male participants who plan to conceive (including sperm or egg donation) and/or are unable to use effective methods during the study period and within 30 days after the end of treatment.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
382 participants (estimated)

Study arms

  • Experimental
    Aprocitentan tablets(SYH9108)

    Drug: Aprocitentan tablets(SYH9108)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • For oral administration

  • DrugPlacebo

    For oral administration. The placebo is identical to aprocitentan tablets(SYH9108) in appearance.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Sitting Systolic Blood Pressure (SiSBP) after 8 weeks of treatment.

    To assess the effect of treatment with Aprocitentan tablets(SYH9108) versus placebo on SiSBP at Week 8.

    Time frame: Baseline and week 8

Secondary outcomes

  1. Change from baseline in SiSBP after 4 weeks of treatment

    To assess the effect of treatment with Aprocitentan tablets(SYH9108) versus placebo.

    Time frame: Baseline and week 4

  2. Change from baseline in Sitting Diastolic Blood Pressure (SiSDP) after 4 weeks of treatment.

    To assess the effect of treatment with Aprocitentan tablets(SYH9108) versus placebo.

    Time frame: Baseline and week 4

  3. Change from baseline in SiSDP after 8 weeks of treatment.

    To assess the effect of treatment with Aprocitentan tablets(SYH9108) versus placebo.

    Time frame: Baseline and week 8

  4. Change from baseline in ambulatory 24-hour average SBP after 4 weeks of treatment.

    To assess the effect of treatment with Aprocitentan tablets(SYH9108) versus placebo.

    Time frame: Baseline and week 4

  5. Change from baseline in ambulatory 24-hour average SDP after 4 weeks of treatment.

    To assess the effect of treatment with Aprocitentan tablets(SYH9108) versus placebo.

    Time frame: Baseline and week 4

  6. Change from baseline in ambulatory 24-hour average SBP after 8 weeks of treatment.

    To assess the effect of treatment with Aprocitentan tablets(SYH9108) versus placebo

    Time frame: Baseline and week 8

  7. Change from baseline in ambulatory 24-hour average SDP after 8 weeks of treatment.

    To assess the effect of treatment with Aprocitentan tablets(SYH9108) versus placebo

    Time frame: Baseline and week 8

  8. Change from baseline in ambulatory night-time average SBP after 4 weeks of treatment.

    To assess the effect of treatment with Aprocitentan tablets(SYH9108) versus placebo.

    Time frame: Baseline and week 4

  9. Change from baseline in ambulatory night-time average SDP after 4 weeks of treatment.

    To assess the effect of treatment with Aprocitentan tablets(SYH9108) versus placebo.

    Time frame: Baseline and week 4

  10. Change from baseline in ambulatory night-time average SBP after 8 weeks of treatment.

    To assess the effect of treatment with Aprocitentan tablets(SYH9108) versus placebo.

    Time frame: Baseline and week 8

  11. Change from baseline in ambulatory night-time average SDP after 8 weeks of treatment.

    To assess the effect of treatment with Aprocitentan tablets(SYH9108) versus placebo.

    Time frame: Baseline and week 8

  12. Change from baseline in ambulatory daytime average SBP after 4 weeks of treatment.

    To assess the effect of treatment with Aprocitentan tablets(SYH9108) versus placebo.

    Time frame: Baseline and week 4

  13. Change from baseline in ambulatory daytime average SDP after 4 weeks of treatment.

    To assess the effect of treatment with Aprocitentan tablets(SYH9108) versus placebo.

    Time frame: Baseline and week 4

  14. Change from baseline in ambulatory daytime average SBP after 8 weeks of treatment.

    To assess the effect of treatment with Aprocitentan tablets(SYH9108) versus placebo.

    Time frame: Baseline and week 8

  15. Change from baseline in ambulatory daytime average SDP after 8 weeks of treatment.

    To assess the effect of treatment with Aprocitentan tablets(SYH9108) versus placebo.

    Time frame: Baseline and week 8

  16. Number of Participants with Treatment Emergent Adverse Events (TEAEs).

    AEs will be assessed using Mild/moderate/severe.

    Time frame: Baseline up to approximately Week 10

  17. Number of Participants with Serious Adverse Events (SAEs).

    AEs will be assessed using Mild/moderate/severe.

    Time frame: Baseline up to approximately Week 10

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Dec 2029, 42 months later.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 42 months is above that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 9, 2026
StartEst.
May 31, 2026
Primary completionEst.
Dec 28, 2029
CompletionEst.
May 31, 2030
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07635914
Responsible party
Sponsor
First posted
Jun 9, 2026
Start date
May 31, 2026 (estimated)
Primary completion
Dec 28, 2029 (estimated)
Completion
May 31, 2030 (estimated)
Last update
Jun 9, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
+86311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aprocitentan

Start the discussion